Daiwa Securities Group Upgrades Merck & Co., Inc. (NYSE:MRK) to “Outperform”

Merck & Co., Inc. (NYSE:MRK) was upgraded by Daiwa Securities Group from a “neutral” rating to an “outperform” rating in a note issued to investors on Wednesday, MarketBeat reports. The firm currently has a $143.00 price objective on the stock. Daiwa Securities Group’s price target would suggest a potential upside of 9.71% from the company’s current price.

Other equities analysts have also recently issued research reports about the stock. Bank of America raised their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Weiss Ratings lowered Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Morgan Stanley increased their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Citigroup assumed coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price on the stock. Finally, CICC Research started coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 target price on the stock. Fifteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $135.50.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $130.35 on Wednesday. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The firm has a fifty day simple moving average of $124.58 and a two-hundred day simple moving average of $119.47. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $135.05. The firm has a market capitalization of $321.59 billion, a PE ratio of 104.28, a price-to-earnings-growth ratio of 5.66 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the firm earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts forecast that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Insider Activity

In related news, EVP David Michael Williams sold 52,847 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the transaction, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Chirfi Guindo sold 15,000 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the sale, the executive vice president directly owned 46,613 shares of the company’s stock, valued at $6,106,303. The trade was a 24.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 92,603 shares of company stock valued at $11,966,744 in the last three months. 0.17% of the stock is owned by company insiders.

Institutional Trading of Merck & Co., Inc.

A number of hedge funds have recently bought and sold shares of MRK. Norges Bank purchased a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $3,997,933,000. Wellington Management Group LLP lifted its position in shares of Merck & Co., Inc. by 14.8% during the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after buying an additional 11,156,354 shares during the last quarter. Cardano Risk Management B.V. bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth $1,012,530,000. Jennison Associates LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth $585,192,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in Merck & Co., Inc. by 37.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock worth $1,973,983,000 after acquiring an additional 5,152,069 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Argus raised its price target to $145 and reiterated a “Buy” rating, implying additional upside from recent levels. The move adds to a generally favorable analyst view, with Merck carrying a “Moderate Buy” consensus rating. Argus raises Merck price target
• Positive Sentiment: Erste Group Bank increased its FY2026 earnings estimate to $2.75 per share from $2.70, broadly in line with the $2.76 consensus forecast. The revision signals modestly improved expectations for Merck’s profitability. Erste Group Bank earnings estimate update
• Positive Sentiment: The FDA and European Medicines Agency accepted applications to expand ENFLONSIA for RSV prevention in additional high-risk young children. Broader approval could strengthen Merck’s vaccine and infectious-disease portfolio and help diversify revenue as Keytruda faces future patent pressure. Merck wins FDA and EMA review for broader RSV use
• Neutral Sentiment: Merck’s latest quarter included $16.61 billion in revenue, ahead of estimates, with oncology and animal health supporting growth. However, reported EPS was negative because of significant charges, while full-year 2026 guidance remains $2.66–$2.76 per share. Merck Q2 2026 earnings call transcript
• Negative Sentiment: Analysts continue to flag declining estimates and upcoming patent expirations, particularly the long-term risk to Keytruda, Merck’s major growth driver. These concerns could limit near-term upside despite pipeline progress. Merck stock outlook amid falling estimates and patent risks
• Negative Sentiment: Executive Vice President Richard Deluca sold 6,050 shares worth approximately $788,799. The transaction reduced his direct holdings by 3.75%, although insider sales alone do not necessarily indicate a change in the company’s fundamentals. Merck executive stock sale

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.